Pular para o conteúdo
Merck
Todas as fotos(2)

Key Documents

GF58573648

Lutetium

powder, 1g, max. particle size 500 micron, 99.9%

Sinônimo(s):

Lutetium, LU006010

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
Lu
Número CAS:
Peso molecular:
174.97
Número MDL:
Código UNSPSC:
11101711
ID de substância PubChem:
NACRES:
NA.23

Ensaio

99.9%

forma

powder

fabricante/nome comercial

Goodfellow 585-736-48

resistividade

54 μΩ-cm, 20°C

tamanho de partícula

500 μm

pb

3402 °C (lit.)

pf

1663 °C (lit.)

densidade

9.84 g/mL at 25 °C (lit.)

cadeia de caracteres SMILES

[Lu]

InChI

1S/Lu

chave InChI

OHSVLFRHMCKCQY-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

For updated SDS information please visit www.goodfellow.com.

Informações legais

Product of Goodfellow

Pictogramas

Flame

Palavra indicadora

Danger

Frases de perigo

Declarações de precaução

Classificações de perigo

Flam. Sol. 1

Código de classe de armazenamento

4.1B - Flammable solid hazardous materials

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

R O Perez et al.
Techniques in coloproctology, 18(8), 699-708 (2014-02-11)
Molecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant
B L R Kam et al.
European journal of nuclear medicine and molecular imaging, 39 Suppl 1, S103-S112 (2012-03-06)
Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). The
S Panigone et al.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 50(4), 310-321 (2006-10-18)
Optimization of therapy for individual patients remains a goal of clinical practice. Radionuclide imaging can identify those patients who may benefit from subsequent targeted therapy by providing regional information on the distribution of the target. An ideal situation may be
Constantin Lapa et al.
Nuclear medicine and biology, 42(4), 349-354 (2015-01-18)
Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). Assessment of
Constantin Lapa et al.
Annals of medicine, 47(7), 538-545 (2015-10-30)
Brown adipose tissue (BAT) attracts growing interest as a potential therapeutic target for obesity and diabetes. Hyperthyroidism is well-known to increase BAT activity, but the role of hypothyroidism is controversial. We aimed to investigate the association between different thyroid hormone

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica